$COCH
Envoy Medical, Inc. Stock $coch

$coch Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024043566 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$68.00K	$59.00K	$0.00
YoY Change
Cost Of Revenue	$245.0K	$153.0K	$175.0K
YoY Change	51.23%	-12.57%
Gross Profit	-$177.0K	-$94.00K	-$175.0K
YoY Change	9.26%	-46.29%
Gross Profit Margin	-260.29%	-159.32%
Selling, General & Admin	$2.092M	$2.444M	$1.747M
YoY Change	-6.1%	39.9%
% of Gross Profit
Research & Development	$2.591M	$2.360M	$1.927M
YoY Change	20.34%	22.47%
% of Gross Profit
Depreciation & Amortization	$42.00K	$34.00K	$27.00K
YoY Change		25.93%
% of Gross Profit
Operating Expenses	$4.683M	$4.804M	$2.493M
YoY Change	4649.49%	92.73%	67.39%
Operating Profit	-$4.860M	-$4.898M	-$2.493M
YoY Change	4829.21%	96.5%	67.39%
Interest Expense	$669.0K	-$1.110M	$3.370M
YoY Change	74.43%	-132.94%	-76.66%
% of Operating Profit
Other Income/Expense, Net	$913.0K	-$1.372M	$681.5K
YoY Change	-170.13%	-301.31%	-239.87%
Pretax Income	-$3.947M	-$6.270M	$1.559M
YoY Change	288.1%	-502.12%	-87.49%
Income Tax			$841.5K
% Of Pretax Income			53.97%
Net Earnings	-$3.947M	-$6.270M	$717.7K
YoY Change	246.76%	-973.62%	-94.24%
Net Earnings / Revenue	-5804.41%	-10627.12%
Basic Earnings Per Share	-$0.27	-$0.32	-$1.31
Diluted Earnings Per Share	-$0.27	-$0.32	$0.02
COMMON SHARES
Basic Shares Outstanding	19.60M shares	19.60M shares	10.12M shares
Diluted Shares Outstanding	19.60M shares	19.60M shares	10.12M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.746M	$4.945M	$104.0K
YoY Change	1215.06%	4653.89%	-18.17%
Cash & Equivalents	$1.746M	$4.945M	$104.0K
Short-Term Investments
Other Short-Term Assets	$1.466M	$1.109M	$412.9K
YoY Change	453.37%	168.59%	-33.1%
Inventory	$1.582M	$1.455M
Prepaid Expenses			$412.9K
Receivables	$174.0K	$189.0K
Other Receivables	$28.00K	$32.00K
Total Short-Term Assets	$4.996M	$7.730M	$516.9K
YoY Change	1156.23%	1395.41%	-30.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$632.0K	$317.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$44.37M
YoY Change			-89.56%
Other Assets			$1.035M
YoY Change			100.81%
Total Long-Term Assets	$1.741M	$750.0K	$45.40M
YoY Change	-96.1%	-98.35%	-89.33%
TOTAL ASSETS
Total Short-Term Assets	$4.996M	$7.730M	$516.9K
Total Long-Term Assets	$1.741M	$750.0K	$45.40M
Total Assets	$6.737M	$8.480M	$45.92M
YoY Change	-85.04%	-81.53%	-89.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.589M	$913.0K	$1.566M
YoY Change	11.0%	-41.69%	137.64%
Accrued Expenses	$6.004M	$5.621M	$5.546M
YoY Change	17.18%	1.36%	110.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$2.234M
YoY Change	-100.0%	-100.0%	197.91%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.058M	$6.996M	$9.499M
YoY Change	-13.79%	-26.35%	134.63%
LONG-TERM LIABILITIES
Long-Term Debt	$7.292M	$4.821M	$0.00
YoY Change
Other Long-Term Liabilities	$3.774M	$4.076M	$11.48M
YoY Change	-68.26%	-64.49%	-46.71%
Total Long-Term Liabilities	$11.07M	$8.897M	$11.48M
YoY Change	-6.93%	-22.49%	-46.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.058M	$6.996M	$9.499M
Total Long-Term Liabilities	$11.07M	$8.897M	$11.48M
Total Liabilities	$19.12M	$15.89M	$20.98M
YoY Change	-9.95%	-24.24%	-18.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$270.2M	-$264.9M	-$19.22M
YoY Change	1199.57%	1277.85%	-20.74%
Common Stock		$179.4K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$12.39M	-$7.413M	-$19.22M
YoY Change
Total Liabilities & Shareholders Equity	$6.737M	$8.480M	$45.92M
YoY Change	-85.04%	-81.53%	-89.23%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$3.947M	-$6.270M	$717.7K
YoY Change	246.76%	-973.62%	-94.24%
Depreciation, Depletion And Amortization	$42.00K	$34.00K	$27.00K
YoY Change		25.93%
Cash From Operating Activities	-$4.908M	-$5.846M	-$2.180M
YoY Change	622.89%	168.22%	182.06%
INVESTING ACTIVITIES
Capital Expenditures	$357.0K		$59.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$433.0K	-$109.0K	$389.0M
YoY Change	-271.83%	-100.03%
Cash From Investing Activities	-$790.0K	-$109.0K	$389.0M
YoY Change	-413.49%	-100.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.500M	$6.683M	-386.9M
YoY Change	448.62%	-101.73%	-51683.0%
NET CHANGE
Cash From Operating Activities	-4.908M	-$5.846M	-2.180M
Cash From Investing Activities	-790.0K	-$109.0K	389.0M
Cash From Financing Activities	2.500M	$6.683M	-386.9M
Net Change In Cash	-3.198M	$727.0K	-3.753K
YoY Change	-11223.48%	-19471.17%	-83.5%
FREE CASH FLOW
Cash From Operating Activities	-$4.908M	-$5.846M	-$2.180M
Capital Expenditures	$357.0K		$59.00K
Free Cash Flow	-$5.265M	-$5.846M	-$2.239M
YoY Change		161.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-40133
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	ENVOY MEDICAL, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-1369123
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4875 White Bear Parkway
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	White Bear Lake
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55110
CY2024Q1	dei	City Area Code CityAreaCode	(877)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	900-3277
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19599982	shares
CY2024Q1	us-gaap	Cash Cash	4945000	usd
CY2023Q4	us-gaap	Cash Cash	4218000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	189000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	70000	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	32000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	176000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1455000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1404000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1109000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	957000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	7730000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6825000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	317000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	351000	usd
CY2024Q1	us-gaap	Assets Assets	8480000	usd
CY2023Q4	us-gaap	Assets Assets	7640000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	913000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1554000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5621000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4613000	usd
CY2024Q1	coch	Product Warranty Liability Current Portion ProductWarrantyLiabilityCurrentPortion	305000	usd
CY2023Q4	coch	Product Warranty Liability Current Portion ProductWarrantyLiabilityCurrentPortion	311000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6996000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6636000	usd
CY2024Q1	coch	Product Warranty Liability Net Of Current Portion ProductWarrantyLiabilityNetOfCurrentPortion	1923000	usd
CY2023Q4	coch	Product Warranty Liability Net Of Current Portion ProductWarrantyLiabilityNetOfCurrentPortion	1923000	usd
CY2024Q1	coch	Publicly Traded Warrant Liability Noncurrent PubliclyTradedWarrantLiabilityNoncurrent	1509000	usd
CY2023Q4	coch	Publicly Traded Warrant Liability Noncurrent PubliclyTradedWarrantLiabilityNoncurrent	332000	usd
CY2023Q4	coch	Forward Purchase Agreement Put Option Liability Noncurrent ForwardPurchaseAgreementPutOptionLiabilityNoncurrent	103000	usd
CY2024Q1	coch	Forward Purchase Agreement Warrant Liability Noncurrent ForwardPurchaseAgreementWarrantLiabilityNoncurrent	266000	usd
CY2023Q4	coch	Forward Purchase Agreement Warrant Liability Noncurrent ForwardPurchaseAgreementWarrantLiabilityNoncurrent	4000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	15893000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	9402000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	257581000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	255596000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-264877000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-257242000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-119000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-118000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-7413000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1762000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8480000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7640000	usd
CY2024Q1	us-gaap	Revenues Revenues	59000	usd
CY2023Q1	us-gaap	Revenues Revenues	78000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	153000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	175000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2360000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1927000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	325000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	371000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2119000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1376000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	4957000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	3849000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4898000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3771000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-9377000	usd
CY2024Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	103000	usd
CY2024Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-262000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1177000	usd
CY2024Q1	us-gaap	Interest Expense Other InterestExpenseOther	36000	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	105000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1372000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9482000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6270000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13253000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6270000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13253000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19599982	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10122581	shares
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6271000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13253000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1762000	usd
CY2024Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1365000	usd
CY2024Q1	coch	Adjustments To Additional Paid In Capital Sale Of Common Stock Associated With Forward Purchase Agreement AdjustmentsToAdditionalPaidInCapitalSaleOfCommonStockAssociatedWithForwardPurchaseAgreement	1683000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	123000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	179000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6270000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-7413000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-36195000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	1952000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13253000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-47495000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6270000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13253000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	34000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	27000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	123000	usd
CY2023Q1	coch	Change In Fair Value Of Warrant Liabilityrelated Party ChangeInFairValueOfWarrantLiabilityrelatedParty	9377000	usd
CY2023Q1	coch	Other Expense Related To Warrant Liabilityrelated Party OtherExpenseRelatedToWarrantLiabilityrelatedParty	-104000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1177000	usd
CY2024Q1	coch	Change In Fair Value Of Forward Purchase Agreement Warrant Liability ChangeInFairValueOfForwardPurchaseAgreementWarrantLiability	-262000	usd
CY2024Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-103000	usd
CY2024Q1	coch	Change In Operating Lease Rightofuse Assetsrelated Party ChangeInOperatingLeaseRightofuseAssetsrelatedParty	31000	usd
CY2023Q1	coch	Change In Operating Lease Rightofuse Assetsrelated Party ChangeInOperatingLeaseRightofuseAssetsrelatedParty	22000	usd
CY2024Q1	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	89000	usd
CY2023Q1	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-14000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	119000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-144000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-28000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	140000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	43000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	37000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-641000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1018000	usd
CY2024Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-27000	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-19000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-357000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-180000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-6000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-62000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5846000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3011000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59000	usd
CY2024Q1	us-gaap	Payments For Other Deposits PaymentsForOtherDeposits	109000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-109000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-59000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4000000	usd
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	5000000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1683000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6683000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4000000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	727000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	931000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4218000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	183000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4945000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1114000	usd
CY2023Q1	coch	Deemed Capital Contribution From Related Party DeemedCapitalContributionFromRelatedParty	1952000	usd
CY2024Q1	coch	Dividends On Series A Preferred Shares DividendsOnSeriesAPreferredShares	1365000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	425606	shares
CY2024Q1	us-gaap	Prepayment Fees On Advances Net PrepaymentFeesOnAdvancesNet	4500000	usd
CY2024Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	8512	shares
CY2024Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	4
CY2024Q1	coch	Proceeds From Purchase Agreement Amount ProceedsFromPurchaseAgreementAmount	1700000	usd
CY2023Q2	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	10000000	usd
CY2024Q1	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	264900000	usd
CY2024Q1	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	5000000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Other Receivables ProceedsFromSaleOfOtherReceivables	1700000	usd
CY2023Q3	us-gaap	Securities Purchased Under Agreements To Resell SecuritiesPurchasedUnderAgreementsToResell	11700000	usd
CY2024Q1	us-gaap	Cash Cash	4900000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include but are not limited to the useful lives of property and equipment, inventory reserves, warranty liability, stock-based compensation expense, the fair value of forward purchase agreement put option liability, the fair value of forward purchase agreement warrant liability and the outcome of litigation. Estimates and assumptions are reviewed periodically and the effect of changes, if any, are reflected in the unaudited condensed consolidated statements of operations and comprehensive loss.</span></p>
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reclassification</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain items in prior financial statements have been reclassified to conform to the current presentation.</span></p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Credit Risk and Significant Customers</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and accounts receivable, net. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral. There have been no material losses on the Company’s accounts receivable. There were no customers that accounted for 10.0% or more of sales for the three months ended March 31, 2024 and 2023, respectively. There were no customers that accounted for 10.0% or more of the accounts receivable balance as of March 31, 2024 and December 31, 2023, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify"> </p>
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	2200000	usd
CY2024Q1	coch	Warranty Liability WarrantyLiability	2200000	usd
CY2023Q4	coch	Warranty Liability WarrantyLiability	2200000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	300000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	300000	usd
CY2024Q1	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-6300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13300000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	pure
CY2024Q1	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1 NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1	8512	shares
CY2024Q1	coch	Purchase Transaction Price PurchaseTransactionPrice	10
CY2024Q1	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1	10000000	usd
CY2024Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.12	pure
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1244000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1162000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	105000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	158000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	106000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	84000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1455000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1404000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	97000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	97000	usd
CY2024Q1	coch	Schedule Of Other Supplemental Information ScheduleOfOtherSupplementalInformation	<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other supplemental information of lease amounts recognized in the unaudited condensed consolidated financial statements is summarized as follows:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">113</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">111</td><td style="width: 1%; text-align: left"> </td></tr> </table>
CY2024Q1	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	113000	usd
CY2023Q1	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	111000	usd
CY2024Q1	coch	Schedule Of Weighted Average Operating Lease ScheduleOfWeightedAverageOperatingLease	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Weighted-average remaining lease term (in years)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3.9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted-average discount rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left">%</td></tr> </table>
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	135000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	154000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	155000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	99000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	543000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	535000	usd
CY2024Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2234000	usd
CY2024Q1	coch	Standard Product Warranty Utilization StandardProductWarrantyUtilization	-6000	usd
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	2228000	usd
CY2024Q1	us-gaap	Unrecovered Production Costs Excess Of Estimated Average Unit Cost UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost	6000	usd
CY2024Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P5Y
CY2024Q1	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.036	pure
CY2024Q1	coch	Discount Rate DiscountRate	0.05	pure
CY2024Q1	coch	Withdrawal Of Funds WithdrawalOfFunds	5000000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.24
CY2024Q1	coch	Expiration Date ExpirationDate	2027-02-27
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	179380	usd
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	500000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	100000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	11.5
CY2024Q1	us-gaap	Auction Market Preferred Securities Stock Series Par Value Per Share AuctionMarketPreferredSecuritiesStockSeriesParValuePerShare	15
CY2024Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.12	pure
CY2024Q1	us-gaap	Other Additional Capital OtherAdditionalCapital	10000000	usd
CY2024Q1	coch	Unpaid Dividend UnpaidDividend	1500000	usd
CY2023Q4	coch	Unpaid Dividend UnpaidDividend	800000	usd
CY2024Q1	us-gaap	Preferred Stock Dividends Per Share Cash Paid PreferredStockDividendsPerShareCashPaid	10
CY2023Q2	coch	Expire Term For Grant ExpireTermForGrant	P10Y
CY2023Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	2.4
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	720505	shares
CY2024Q1	coch	Percentage Of Stock Options Vested PercentageOfStockOptionsVested	0.50	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1967734	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.38
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	31955	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.35
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1999689	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.37
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M25D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3103871000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	934673	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.4
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9Y6M18D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1420703000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	500000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	500000	usd
CY2024Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	50000	usd
CY2023	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	50000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6270000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13253000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13253000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6270000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13253000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19599982	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10122581	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19599982	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10122581	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21079398	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	263000	shares
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
CY2023Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
CY2023Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment		usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther		usd
CY2024Q1	us-gaap	Other Expenses OtherExpenses		usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13253000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6270000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10122581	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19599982	shares
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent		usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2024Q1	coch	Change In Fair Value Of Warrant Liabilityrelated Party ChangeInFairValueOfWarrantLiabilityrelatedParty		usd
CY2024Q1	coch	Other Expense Related To Warrant Liabilityrelated Party OtherExpenseRelatedToWarrantLiabilityrelatedParty		usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q1	coch	Change In Fair Value Of Forward Purchase Agreement Warrant Liability ChangeInFairValueOfForwardPurchaseAgreementWarrantLiability		usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023Q1	us-gaap	Payments For Other Deposits PaymentsForOtherDeposits		usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2024Q1	us-gaap	Interest Paid InterestPaid		usd
CY2023Q1	us-gaap	Interest Paid InterestPaid		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	coch	Deemed Capital Contribution From Related Party DeemedCapitalContributionFromRelatedParty		usd
CY2023Q1	coch	Dividends On Series A Preferred Shares DividendsOnSeriesAPreferredShares		usd
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	coch	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2024Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted		usd
CY2023Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted		usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001840877

Files In Submission

Name	View Source	Status
0001213900-24-043566-index-headers.html	Edgar Link	pending
0001213900-24-043566-index.html	Edgar Link	pending
0001213900-24-043566.txt	Edgar Link	pending
0001213900-24-043566-xbrl.zip	Edgar Link	pending
coch-20240331.xsd	Edgar Link	pending
ea0205837-10q_envoy.htm	Edgar Link	pending
ea020583701ex10-1_envoy.htm	Edgar Link	pending
ea020583701ex10-2_envoy.htm	Edgar Link	pending
ea020583701ex31-1_envoy.htm	Edgar Link	pending
ea020583701ex31-2_envoy.htm	Edgar Link	pending
ea020583701ex32-1_envoy.htm	Edgar Link	pending
ea020583701ex32-2_envoy.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
coch-20240331_def.xml	Edgar Link	unprocessable
coch-20240331_lab.xml	Edgar Link	unprocessable
coch-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0205837-10q_envoy_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
coch-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$COCH
Envoy Medical, Inc. Stock $coch

2024 Q2 Form 10-Q Financial Statement

#000121390024043566 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCH Envoy Medical, Inc. Stock $coch

2024 Q2 Form 10-Q Financial Statement

#000121390024043566 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCH
Envoy Medical, Inc. Stock $coch